时迈药业递表港交所

Core Viewpoint - Zhejiang Shimai Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, positioning itself as a pioneer and global leader in next-generation T-cell engagers (TCE) therapy [1]. Company Overview - Established in 2017, the company focuses on TCE, which are bispecific or multispecific antibodies designed to target tumor-associated antigens (TAA) on cancer cells and receptors on T-cells, thereby directing T-cells to tumor tissues and activating them to induce targeted cytotoxic effects [1]. - The company recognized the differentiated potential of TCE early on, aiming to leverage and guide the human immune system to combat cancer through next-generation immunotherapy [1]. Product Pipeline - As of November 5, 2025, the company has four self-developed clinical-stage drug candidates: 1. DNV3, a potential best-in-class T-cell modulator targeting LAG3 2. SMET12, a potential first-in-class intravenous EGFR×CD3 TCE 3. CMD011, a potential best-in-class GPC3×CD3 TCE 4. CMDE005, a potential first-in-class next-generation shielding TCE targeting EGFR×CD3 [3]. - Additionally, the company has two preclinical-stage next-generation multifunctional/logical gate TCE candidates, CMDE101 and CMDE102, targeting FOLR1×PD-L1×CD3 and PSMA×PD-L1×CD3, respectively [3].